研究论文
Hepatic Pseudoprogression after Treatment with Nectin-4–Targeted Antibody–Drug Conjugate
ShanBing Wang, Jiapei Liu, Fang Xie
Second People’s Hospital of Yibin
来源New England Journal of Medicine
年份2026
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 完整
In a patient with metastatic cervical cancer treated with the nectin-4–targeted antibody–drug conjugate bulumtatug fuvedotin, a new hepatic lesion proved to be pseudoprogression and resolved with continued therapy.
逐年被引趋势
暂无年度引用数据
关键指标
0
被引次数 · OpenAlex
0.00
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 68%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
5
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：摘要
论文问答
当前基于摘要回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学HER2/EGFR in Cancer Research
Immune Cell Function and Interaction · T-cell and B-cell Immunology
参考文献 5
LyRIC indeterminate response and Immune‐mediated pseudoprogression of diffuse large B‐cell lymphoma following polatuzumab‐based salvage therapy
被引 4Alexander T.J. Lee, Ayoma D. Attygale, Rajaei K. Sharma · British Journal of Haematology · 2020
Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy
被引 3Xin Wang, Lacey McIntosh, William Selove · Leukemia & lymphoma/Leukemia and lymphoma · 2021
Pooled Rate of Pseudoprogression, Patterns of Response, and Tumor Burden Analysis in Patients Undergoing Immunotherapy Oncologic Trials for Different Malignancies
被引 11S. Morrissey, A.G. Vasconcelos, Carolyn L. Wang · Clinical Oncology · 2024
此处列出前 3 条
引用本文 -
暂无引用本文的记录